US20070202199A1 - Compositions for Enhancing Sexual Responsiveness - Google Patents
Compositions for Enhancing Sexual Responsiveness Download PDFInfo
- Publication number
- US20070202199A1 US20070202199A1 US11/745,421 US74542107A US2007202199A1 US 20070202199 A1 US20070202199 A1 US 20070202199A1 US 74542107 A US74542107 A US 74542107A US 2007202199 A1 US2007202199 A1 US 2007202199A1
- Authority
- US
- United States
- Prior art keywords
- composition
- compositions
- methyl
- water
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 128
- 230000002708 enhancing effect Effects 0.000 title claims 2
- 230000004043 responsiveness Effects 0.000 title abstract description 3
- 230000001568 sexual effect Effects 0.000 title abstract description 3
- 230000000699 topical effect Effects 0.000 claims abstract description 51
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 claims description 46
- 229960001238 methylnicotinate Drugs 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 19
- 235000014852 L-arginine Nutrition 0.000 claims description 19
- 229930064664 L-arginine Natural products 0.000 claims description 19
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 14
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 14
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 14
- 241001116389 Aloe Species 0.000 claims description 11
- 235000011399 aloe vera Nutrition 0.000 claims description 11
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 9
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- 229960000541 cetyl alcohol Drugs 0.000 claims description 7
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 7
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 7
- 229960002216 methylparaben Drugs 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 7
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 7
- 229960003415 propylparaben Drugs 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- 230000036332 sexual response Effects 0.000 claims description 6
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 5
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 5
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 5
- 238000011200 topical administration Methods 0.000 claims description 5
- 230000000304 vasodilatating effect Effects 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims 6
- 239000003981 vehicle Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- 229940094952 green tea extract Drugs 0.000 claims 4
- 235000020688 green tea extract Nutrition 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229960004274 stearic acid Drugs 0.000 claims 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims 2
- 235000019486 Sunflower oil Nutrition 0.000 claims 2
- 235000012424 soybean oil Nutrition 0.000 claims 2
- 239000003549 soybean oil Substances 0.000 claims 2
- 239000002600 sunflower oil Substances 0.000 claims 2
- 229940042585 tocopherol acetate Drugs 0.000 claims 2
- 210000003899 penis Anatomy 0.000 abstract description 9
- 241001313288 Labia Species 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 239000000810 peripheral vasodilating agent Substances 0.000 abstract 1
- 229960002116 peripheral vasodilator Drugs 0.000 abstract 1
- 239000003087 receptor blocking agent Substances 0.000 abstract 1
- 239000005526 vasoconstrictor agent Substances 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 45
- 240000000759 Lepidium meyenii Species 0.000 description 19
- 235000000421 Lepidium meyenii Nutrition 0.000 description 16
- 241000340987 Ptychopetalum olacoides Species 0.000 description 16
- 235000012902 lepidium meyenii Nutrition 0.000 description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 15
- 239000010018 saw palmetto extract Substances 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 235000008690 Pausinystalia yohimbe Nutrition 0.000 description 8
- 240000006661 Serenoa repens Species 0.000 description 8
- 235000005318 Serenoa repens Nutrition 0.000 description 8
- 235000009108 Urtica dioica Nutrition 0.000 description 8
- 235000020735 yohimbe extract Nutrition 0.000 description 8
- 229940063845 saw palmetto extract Drugs 0.000 description 7
- 235000019165 vitamin E Nutrition 0.000 description 7
- 239000011709 vitamin E Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 244000068988 Glycine max Species 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 6
- 244000020551 Helianthus annuus Species 0.000 description 6
- 235000003222 Helianthus annuus Nutrition 0.000 description 6
- 240000007817 Olea europaea Species 0.000 description 6
- 240000004371 Panax ginseng Species 0.000 description 6
- 244000178231 Rosmarinus officinalis Species 0.000 description 6
- 241000218215 Urticaceae Species 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- 239000001140 aloe barbadensis leaf extract Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
- 235000008434 ginseng Nutrition 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 6
- 229940046009 vitamin E Drugs 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 239000012676 herbal extract Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000004357 Mentha x piperita Nutrition 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 235000020710 ginseng extract Nutrition 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 235000016804 zinc Nutrition 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 244000276331 Citrus maxima Species 0.000 description 3
- 235000001759 Citrus maxima Nutrition 0.000 description 3
- 240000000560 Citrus x paradisi Species 0.000 description 3
- 235000002725 Olea europaea Nutrition 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 244000209710 Samanea saman Species 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011928 denatured alcohol Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000008387 emulsifying waxe Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 229960001047 methyl salicylate Drugs 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000002831 pharmacologic agent Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 240000004784 Cymbopogon citratus Species 0.000 description 2
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 241001479543 Mentha x piperita Species 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 244000274883 Urtica dioica Species 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001771 mentha piperita Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 230000007103 stamina Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 235000000504 Dioscorea villosa Nutrition 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010024421 Libido increased Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 206010052004 Organic erectile dysfunction Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010040108 Serotonin syndrome Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000003048 aphrodisiac agent Substances 0.000 description 1
- 230000002509 aphrodisiac effect Effects 0.000 description 1
- 229940003587 aquaphor Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 210000005226 corpus cavernosum Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000011264 priapism Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 239000003542 rubefacient Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940100617 topical lotion Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 239000000083 urinary anti-infective agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- MTZBBNMLMNBNJL-UHFFFAOYSA-N xipamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(S(N)(=O)=O)=C(Cl)C=C1O MTZBBNMLMNBNJL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Definitions
- the invention relates to a topically-administered compositions for the enhancement of sexual responsiveness in mammals.
- the male sexual response includes the filling of vascular channels that are empty in the flaccid penis, with blood at pressures approaching systemic levels. Erection occurs when the arteriolar and sinusoidal smooth muscles of the vessels within the corpora relax, thus lowering resistance in these channels and allowing arterial blood to surge into the penis. Exit of the arterial blood is simultaneously impeded by an increase in venous resistance. Further distention of the sinusoids is restrained by the minimally distensible tunica albuginea that raises the pressure further and also restricts venous outflow. Thus, the corpora cavernosa and corpus spongiosum can be filled with blood and the penis can be erect with little demand on cardiac output. These vascular changes that occur during erection are thought to be controlled by vasoactive intestinal polypeptide, perhaps aided by alpha-adrenergic blockade, acetylcholine and nitric oxide.
- the female sexual response cycle is typically divided into four phases including desire, excitement, which includes physiological changes such as vasocongestion in the pelvis, vaginal lubrication, and expansion and swelling of the external genitalia, orgasm, and resolution.
- Disorders of female sexual desire or response are estimated to affect from 30 to 50 percent of the adult female population. These disorders may have a variety of causes including psychogenic etiologies, anatomical disorders, drug-induced disorders, diabetes mellitus, post-surgical disorders, atherosclerosis, post-traumatic disorders, as well as endocrine etiologies.
- effective treatment may be had by overcoming any boundaries to the physiological changes that take place during excitement including vasocongestion.
- pharmacological agents used for the enhancement of erection and treatment of sexual dysfunction and as pro-libido agents.
- Some examples include: serotonin receptor agonists and antagonists (see, e.g., EP 385,658; WO 94/15,920; GB 2,248,449; and GB 2,276,165), dopamine receptor agonists (see, e.g., WO 93/23,035; WO 94/21,608; Pomerantz S. M., Pharmacol. Biochem. Behav. 39:123-128, 1991; and Ferrari F. et al.
- adrenergic receptor agonists see, e.g., WO 95/13,072; EP 611,248; U.S. Pat. No. 5,229,387; and WO 92/11,851
- inhibitors of phosphodiesterase see, e.g., DE 4,338,948; and WO 94/28,902
- histamine receptor agonists see, e.g., U.S. Pat. Nos. 4,013,659; 4,126,670; 4,767,778; WO 91/17,146; U.S. Pat. No.
- neuropeptide Y antagonists see, e.g., WO 95/00,161
- angiotensin II receptor antagonists see, e.g., EP 577,025
- cholinesterase inhibitors see, e.g., U.S. Pat. Nos. 5,177,070; and 4,633,318
- combinations of agents with the different types of biological activity see, e.g., U.S. Pat. No. 5,145,852; and WO 95/05,188
- derivatives of vasoactive intestinal peptide see, e.g., U.S. Pat. No.
- nitric oxide donors see, e.g., WO 92/21,346; DE 4,305,881; DE 4,212,582; and WO 94/16,729); calcitonin gene related peptide (see, e.g., Steif, C. G. et al., Urology, 41:397-400, 1993); and androgens (see, e.g., JP 06,211,675; HU 62,473; and WO 94/16,709).
- pharmacological agents are associated with adverse effects including aggravation or induction of schizophrenia, serotonin syndrome, central nervous system and endocrine system dysfunction, pain, echytomosis and priapism.
- the compositions contains between about 0.1% and about 5% methyl nicotinate, between about 5 drops and about 50 drops of yohimbe extract, between about 0.3% and about 1.5% L-arginine; between about 1 drop and about 30 drops of muira puama extract per four ounces of composition, between about 1 drop and about 30 drops of catuaba extract per four ounces of composition, between about 1 drop and about 30 drops of maca extract per four ounces of composition, and between about 1 drop and about 30 drops of saw palmetto extract per four ounces of composition in a pharmaceutically-acceptable topical vehicle.
- compositions of the present invention are formulated in a topical lotion containing aloe and vitamin E.
- Another preferred embodiment is a condom having an internal surface coated with one of the topical compositions of the present invention.
- the topical composition contains about 1% methyl nicotinate, about 25 drops of yohimbe extract, about 8 mg/cm 3 of L-arginine, about 12 drops of muira puama extract, about 12 drops of catuaba extract, about 12 drops of maca extract, and about 12 drops of saw palmetto extract in a pharmaceutically-acceptable water-based topical vehicle containing aloe and vitamin E.
- the topical composition contains about 1% methyl nicotinate, about 8 mg/ml of L-arginine, about 12 drops of muira puama extract, about 12 drops of catuaba extract, and about 12 drops of maca extract, in a pharmaceutically-acceptable water-based topical vehicle containing aloe and vitamin E.
- transitional phrases “comprising”, “consisting essentially of” and “consisting of” define the scope of the appended claims with respect to what un-recited additional components, if any, are excluded from the scope of the claim.
- the term “comprising” is intended to be inclusive or open-ended and does not exclude additional, un-recited elements or method steps.
- the phrase “consisting of” excludes any element, step, or ingredient not specified in the claim.
- the phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s) of the claimed invention. All compositions or formulations identified herein can, in alternate embodiments, be more specifically defined by any of the transitional phrases “comprising”, “consisting essentially of” and “consisting of.”
- compositions of the present invention are formulated with a combination of active ingredients that enhance blood flow to the area applied thereby resulting in erection or vasocongestion.
- the active ingredients in these compositions aid the body in the production of nitric oxide via the essential amino acid L-arginine. Additionally, these compositions function as powerful vasodilators using yohimbe, and methyl nicotinate to increase circulation, discourage clot formation, and reinforce the walls of the capillaries allowing for bigger, thicker blood vessels.
- These physiological actions are believed to be useful for the treatment of sexual dysfunction resulting from circulatory disorders. Additionally, these physiological actions are believed to strengthen blood vessel walls of the penis resulting in erectile enhancement.
- herbal ingredients in these compositions can act to promote and enhance desire functioning as pro-libido agents.
- compositions of the present invention contain one or more of the following active ingredients: methyl nicotinate, yohimbe extract, panax ginseng, L-arginine, muira puama, catuaba bark, maca, and saw palmetto.
- Methyl nicotinate is rubefacient and counterirritant for the relief of aches and pains in muscles, tendons, and joints. When applied to the skin, methyl nicotinate causes vasodilation of the surrounding blood vessels producing a feeling of warmth. This sensation competes with, and to some extent blocks, pain in underlying muscles and joints, since both feelings are conveyed by the same nerves.
- the compositions of the present invention may contain between about 0.1% and about 5% methyl nicotinate. Preferably, the compositions of the present invention contain between about 0.5% and about 2% methyl nicotinate. Most preferably, the compositions of the present invention contain about 1% methyl nicotinate. Suitable sources of methyl nicotinate for use in compositions of the present invention are available commercially. For example, methyl nicotinate is available commercially from Araer Chemicals.
- Yohimbe is a vasodilator used as a sensual stimulant for healthy men and women and to treat organic impotence. Yohimbe is thought to stimulate the pelvic nerve ganglia and is thus useful for the treatment of erection problems. Effects may include increased libido, increased sensation and increased stamina.
- the compositions of the present invention may include yohimbe extract prepared by extracting the yohimbe for one ounce of a plant material containing the herb into two ounces of a suitable liquid. Typically the extraction liquid is water or an alcohol. Prepared in this manner, compositions of the present invention may contain between about 5 drops and about 50 drops of the yohimbe extract in 120 cm 3 of the topical composition of the present invention.
- compositions of the present invention contain between about 15 drops and about 35 drops of the yohimbe extract in four ounces of the topical composition. Most preferably, the compositions of the present invention contain about 25 drops of the yohimbe extract in four ounces of the topical composition.
- Herbal extracts containing yohimbe that are suitable for use in formulating compositions of the present invention are available commercially. For example, an herbal blend containing yohimbe that is suitable for use in compositions of the present invention is commercially available from Nature's Alternative.
- Panax ginseng is an herb thought to be an immune stimulant.
- Ginseng has a high content of the Rg1 group of ginsenosides which cause an increase in motor activity. It acts on the adrenal and pituitary glands and is thought to improve response to stress, increase mental and physical work capacity, increase concentration and mental activity, enhance mental acuity and intellectual and physical performance and benefit the immune system.
- the compositions of the present invention may include ginseng extract prepared by extracting ginseng from one ounce of a plant material containing the herb into two ounces of a suitable liquid. Typically the extraction liquid is water or an alcohol. Prepared in this manner, compositions of the present invention may contain between about 1 drop and about 30 drops of ginseng extract in four ounces of the topical composition.
- compositions of the present invention contain between about 5 drops and about 20 drops of ginseng extract in four ounces of the topical composition. Most preferably, the compositions of the present invention contain about 12 drops of ginseng extract in four ounces of the topical composition.
- Herbal extracts containing ginseng that are suitable for use in formulating compositions of the present invention are available commercially. For example, an herbal blend containing ginseng that is suitable for use in compositions of the present invention is commercially available from Nature's Alternative.
- the compositions of the present invention contain between about 200 mg and about 300 mg of L-arginine per ounce of the topical composition. Most preferably, the compositions of the present invention contain about 240 mg of L-arginine per ounce of the topical composition.
- L-arginine suitable for use in formulating compositions of the present invention is available commercially.
- a commercial source of L-arginine that is suitable for use in compositions of the present invention is commercially available from T. J. Clark.
- Muira puama is a botanical isolated from a tree that grows in the rain forests of Brazil. Used as a mild tonic, this herb is thought to be useful in treating the symptoms of nervous problems and disorders such as neurasthenia, neuralgia and nervous depression.
- the compositions of the present invention may include muira puama extract prepared by extracting one ounce of muira puama plant material into two ounces of a suitable liquid. Typically the extraction liquid is an alcohol. Prepared in this manner, compositions of the present invention may contain between about 1 drop and about 30 drops of muira puama extract in four ounces of the topical composition.
- compositions of the present invention contain between about 5 drops and about 20 drops of muira puama extract in four ounces of the topical composition. Most preferably, the compositions of the present invention contain about 12 drops of muira puama extract in four ounces of the topical composition.
- Herbal extracts of muira puama that are suitable for use in formulating compositions of the present invention are available commercially.
- a concentrated extract that is suitable for use in compositions of the present invention is commercially available from Raintree Nutrition.
- compositions of the present invention may include catuaba extract prepared by extracting one ounce of catuaba bark into two ounces of a suitable liquid. Typically the extraction liquid is water or an alcohol. Prepared in this manner, compositions of the present invention may contain between about 1 drop and about 30 drops of catuaba extract in four ounces of the topical composition. Preferably, the compositions of the present invention contain between about 5 drops and about 20 drops of catuaba extract in four ounces of the topical composition.
- compositions of the present invention contain about 12 drops of catuaba extract in four ounces of the topical composition.
- Herbal extracts containing catauba that are suitable for use in formulating compositions of the present invention are available commercially.
- a catuaba bark extract suitable for use in compositions of the present invention is commercially available from Raintree Nutrition.
- Maca is a plant also known as Lepidium meyenii .
- Peruvian maca root is a vegetable root or tuber related to the potato and the Mexican wild yam. It contains amino acids, complex carbohydrates, vitamins B1, B2, B12, C and E and minerals, including calcium, phosphorus, zinc, magnesium and iron.
- This herb has traditionally been used to increase energy, vitality, stamina and endurance in athletes, promote mental clarity, as an aphrodisiac for both men and women, for male impotence, menstrual irregularities and female hormone imbalances, including menopause.
- the compositions of the present invention may include maca extract prepared by extracting one ounce of maca plant root material into two ounces of a suitable liquid. Typically the extraction liquid is water or an alcohol.
- compositions of the present invention may contain between about 1 drop and about 30 drops of maca extract in four ounces of the topical composition.
- the compositions of the present invention contain between about 5 drops and about 20 drops of maca extract in four ounces of the topical composition.
- the compositions of the present invention contain about 12 drops of maca extract in four ounces of the topical composition.
- Maca plant material suitable for use in preparing extracts for use in formulating compositions of the present invention are available commercially.
- bulk maca plant material that is suitable for use in compositions of the present invention is commercially available from Raintree Nutrition.
- compositions of the present invention may include saw palmetto extract prepared by extracting the saw palmetto from one ounce of a plant material containing the herb into two ounces of a suitable liquid. Typically the extraction liquid is water or an alcohol. Prepared in this manner, compositions of the present invention may contain between about 1 drop and about 30 drops of saw palmetto extract in four ounces of the topical composition. Preferably, the compositions of the present invention contain between about 5 drops and about 20 drops of saw palmetto extract in four ounces of the topical composition.
- compositions of the present invention contain about 12 drops of saw palmetto extract in four ounces of the topical composition.
- Herbal extracts containing saw palmetto that are suitable for use in formulating compositions of the present invention are available commercially.
- a saw palmetto extract that is suitable for use in compositions of the present invention is commercially available from Nature's Alternative.
- compositions of the present invention can optionally include as active ingredients nettles and/or zinc.
- the components are widely available commercially.
- compositions of the present invention may contain other ingredients that are not physiologically active but serve to enhance the pharmaceutical elegance of the final topical composition.
- the compositions of the present invention may contain excipients such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidinone, cellulose, water, syrup, and methyl cellulose.
- the compositions of the present invention may include lubricating agents such as talc, magnesium stearate and mineral oil, wetting agents, emulsifying and suspending agents, preserving agents such as methyl- and propylhydroxybenzoates, sweetening agents or flavoring agents.
- compositions of the present invention may be formulated in any pharmaceutically acceptable topical vehicle that does not interact adversely with the active ingredients or, in the case of the embodiment which includes a coating of the compositions applied to one surface of a condom, does not interact adversely with the condom materials.
- compositions of the present invention may be formulated in water or oil based topical vehicles. These compositions can include lanolin, aquaphor, methylcellulose and derivatives thereof, petroleum based vehicles, aloe and the like.
- the compositions of the present invention are formulated in a topical, water-based vehicle containing aloe and vitamin E. Suitable topical vehicles containing aloe and vitamin E are available commercially.
- a suitable topical vehicle for use in formulating compositions of the present invention containing aloe and vitamin E is available from T. C. Laboratories (Treasures Company).
- the topical compositions of the present invention contain a mixture of distilled water, aloe barbadensis leafjuice, helianthus annus (sunflower) seed oil, stearic acid, glycine soja (soybean) oil, cetyl alcohol NF, emulsifying wax, olea Europaea (olive) fruit oil, glycerin, palmitic acid, cymbopogan schoenanthus (lemongrass) oil, mentha piperita (peppermint) oil, tocopherol, denatured alcohol, methyl salicylate, aloe barbadensis leaf extract, menthol, fragrance, camella sinensis (green tea) leaf extract, rosmarinus officinalis (rosemary) leaf extract, citrus grandis (grapefruit) seed extract, lecithin, sodium bicarbonate, ascorbyl palmitate, polysorbate 20, methylparaben, propylparaben, urtica dio
- compositions of the present invention are formulated for transdermal delivery of the active ingredients following topical administration to the penis or labia inajora and minora pudendi.
- a small amount of the compositions of the present invention is applied topically directly to the penis or labia majora and minora pudendi.
- the composition may be packaged as a coating on the interior surface of a condom. Thereby, upon use of the condom, the composition is applied topically to the penis.
- a preferred embodiment of the topical compositions of the present invention consists essentially of the following ingredients of a quality and purity suitable for topical application to a mammal: Active ingredient Amount per 30 g ⁇ 10% methyl nicotinate 0.3 g yohimbe extract 25 drops L-arginine 240 mg muira puama extract 12 drops catuaba bark extract 12 drops maca extract 12 drops saw palmetto 12 drops
- active ingredients were formulated in a base for topical administration in a pharmaceutically-acceptable topical vehicle containing distilled water, aloe barbadensis leaf juice, helianthus annus (sunflower) seed oil, stearic acid, glycine soja (soybean) oil, cetyl alcohol NF, emulsifying wax, olea Europaea (olive) fruit oil, glycerin, palmitic acid, cymbopogan schoenanthus (lemongrass) oil, mentha piperita (peppermint) oil, tocopherol, denatured alcohol, methyl salicylate, aloe barbadensis leaf extract, camella sinensis (green tea) leaf extract, rosmarinus officinalis (rosemary) leaf extract, citrus grandis (grapefruit) seed extract, lecithin, sodium bicarbonate, ascorbyl palmitate, polysorbate 20, methylparaben, propylparaben, mitica di
- a preferred embodiment of the topical compositions of the present invention consists essentially of the following ingredients of a quality and purity suitable for topical application to a mammal: Active ingredient Amount per 30 g ⁇ 10% methyl nicotinate 0.3 g L-arginine 240 mg muira puama extract 12 drops catuaba bark extract 12 drops maca extract 12 drops
- active ingredients were formulated in a base for topical administration in a pharmaceutically-acceptable topical vehicle containing distilled water, aloe barbadensis leaf juice, helianthus annus (sunflower) seed oil, stearic acid, glycine soja (soybean) oil, cetyl alcohol, emulsifying wax, olea europaea (olive) fruit oil, glycerin, palmitic acid, fragrance, tocopherol, denatured alcohol, methyl salicylate, aloe barbadensis leaf extract, camella sinensis (green tea) leaf extract, rosmarinus officinalis (rosemary) leaf extract, citrus grandis (grapefruit) seed extract, lecithin, sodium bicarbonate, ascorbyl palmitate, polysorbate 20, menthol, methylparaben, propylparaben, urtica dioica (nettles) extract and zinc oxide, having a pH of about 6.0.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A topical composition which enhances sexual responsiveness of a mammal is disclosed. An effective dosage of a peripheral vasodilator, an absorption enhancer and, optionally, a vasoconstrictor and an alpha receptor blocker are combined with a pharmaceutically-acceptable topical vehicle to produce the composition. The compositions are applied topically to the penis or labia majora and minora pudenda to enhance erection or vasocongestion.
Description
- This application is a continuation of U.S. patent application Ser. No. 10/775,574, filed Feb. 9, 2004, now U.S. Pat. No. 7,214,390, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application Ser. No. 60/445,624, filed Feb. 7, 2003. These patent applications are incorporated herein, in their entirety, by this reference.
- The invention relates to a topically-administered compositions for the enhancement of sexual responsiveness in mammals.
- The male sexual response includes the filling of vascular channels that are empty in the flaccid penis, with blood at pressures approaching systemic levels. Erection occurs when the arteriolar and sinusoidal smooth muscles of the vessels within the corpora relax, thus lowering resistance in these channels and allowing arterial blood to surge into the penis. Exit of the arterial blood is simultaneously impeded by an increase in venous resistance. Further distention of the sinusoids is restrained by the minimally distensible tunica albuginea that raises the pressure further and also restricts venous outflow. Thus, the corpora cavernosa and corpus spongiosum can be filled with blood and the penis can be erect with little demand on cardiac output. These vascular changes that occur during erection are thought to be controlled by vasoactive intestinal polypeptide, perhaps aided by alpha-adrenergic blockade, acetylcholine and nitric oxide.
- The female sexual response cycle is typically divided into four phases including desire, excitement, which includes physiological changes such as vasocongestion in the pelvis, vaginal lubrication, and expansion and swelling of the external genitalia, orgasm, and resolution. Disorders of female sexual desire or response are estimated to affect from 30 to 50 percent of the adult female population. These disorders may have a variety of causes including psychogenic etiologies, anatomical disorders, drug-induced disorders, diabetes mellitus, post-surgical disorders, atherosclerosis, post-traumatic disorders, as well as endocrine etiologies. Depending upon the etiology of the disorder, effective treatment may be had by overcoming any boundaries to the physiological changes that take place during excitement including vasocongestion. Thus, in certain cases, it may be possible to enhance the female sexual response by stimulating vasocongestion.
- There are a wide variety of pharmacological agents used for the enhancement of erection and treatment of sexual dysfunction and as pro-libido agents. Some examples include: serotonin receptor agonists and antagonists (see, e.g., EP 385,658; WO 94/15,920; GB 2,248,449; and GB 2,276,165), dopamine receptor agonists (see, e.g., WO 93/23,035; WO 94/21,608; Pomerantz S. M., Pharmacol. Biochem. Behav. 39:123-128, 1991; and Ferrari F. et al. Psychopharmacology 113:172-176, 1993); adrenergic receptor agonists (see, e.g., WO 95/13,072; EP 611,248; U.S. Pat. No. 5,229,387; and WO 92/11,851); inhibitors of phosphodiesterase (see, e.g., DE 4,338,948; and WO 94/28,902); histamine receptor agonists (see, e.g., U.S. Pat. Nos. 4,013,659; 4,126,670; 4,767,778; WO 91/17,146; U.S. Pat. No. 5,047,418; and EP 0,458,661); neuropeptide Y antagonists (see, e.g., WO 95/00,161); angiotensin II receptor antagonists (see, e.g., EP 577,025); cholinesterase inhibitors (see, e.g., U.S. Pat. Nos. 5,177,070; and 4,633,318); combinations of agents with the different types of biological activity (see, e.g., U.S. Pat. No. 5,145,852; and WO 95/05,188); derivatives of vasoactive intestinal peptide (see, e.g., U.S. Pat. No. 5,147,855; EP 540,969; and EP 463,450); prostaglandins (see, e.g., WO 93/00,894; and EP 459,3770); antidepressants and antipsychotics (see, e.g., U.S. Pat. No. 4,931,445; GB 2,448,449; and Naganuma et al. Clin. Exp. Pharm. Physiol. 20:177-183, 1993); nitric oxide donors (see, e.g., WO 92/21,346; DE 4,305,881; DE 4,212,582; and WO 94/16,729); calcitonin gene related peptide (see, e.g., Steif, C. G. et al., Urology, 41:397-400, 1993); and androgens (see, e.g., JP 06,211,675; HU 62,473; and WO 94/16,709). Unfortunately, many or all of these pharmacological agents are associated with adverse effects including aggravation or induction of schizophrenia, serotonin syndrome, central nervous system and endocrine system dysfunction, pain, echytomosis and priapism.
- Accordingly there is a need in the art to identify new pharmacological agents or compositions which are useful for enhancement of the sexual response in mammals.
- One embodiment of the present invention provides a topical composition comprising at least one active ingredient including methyl nicotinate, yohimbe, L-arginine in a pharmaceutically-acceptable topical vehicle. These compositions may also include as least one additional active ingredient including muira puama, catuaba, maca extract, and saw palmetto. In a preferred embodiment, the composition contains methyl nicotinate, yohimbe, L-arginine, muira puama, catuaba, maca extract, saw palmetto, nettles and zinc. In another preferred embodiment, the composition contains methyl nicotinate, L-arginine, muira puama, catuaba, maca extract, nettles and zinc.
- In a particularly preferred embodiment, the compositions contains between about 0.1% and about 5% methyl nicotinate, between about 5 drops and about 50 drops of yohimbe extract, between about 0.3% and about 1.5% L-arginine; between about 1 drop and about 30 drops of muira puama extract per four ounces of composition, between about 1 drop and about 30 drops of catuaba extract per four ounces of composition, between about 1 drop and about 30 drops of maca extract per four ounces of composition, and between about 1 drop and about 30 drops of saw palmetto extract per four ounces of composition in a pharmaceutically-acceptable topical vehicle.
- Preferably, the compositions of the present invention are formulated in a topical lotion containing aloe and vitamin E.
- Another preferred embodiment is a condom having an internal surface coated with one of the topical compositions of the present invention.
- In another particularly preferred embodiment of the present invention the topical composition contains about 1% methyl nicotinate, about 25 drops of yohimbe extract, about 8 mg/cm3 of L-arginine, about 12 drops of muira puama extract, about 12 drops of catuaba extract, about 12 drops of maca extract, and about 12 drops of saw palmetto extract in a pharmaceutically-acceptable water-based topical vehicle containing aloe and vitamin E.
- In another particularly preferred embodiment of the present invention, the topical composition contains about 1% methyl nicotinate, about 8 mg/ml of L-arginine, about 12 drops of muira puama extract, about 12 drops of catuaba extract, and about 12 drops of maca extract, in a pharmaceutically-acceptable water-based topical vehicle containing aloe and vitamin E.
- As used herein, the transitional phrases “comprising”, “consisting essentially of” and “consisting of” define the scope of the appended claims with respect to what un-recited additional components, if any, are excluded from the scope of the claim. The term “comprising” is intended to be inclusive or open-ended and does not exclude additional, un-recited elements or method steps. The phrase “consisting of” excludes any element, step, or ingredient not specified in the claim. The phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s) of the claimed invention. All compositions or formulations identified herein can, in alternate embodiments, be more specifically defined by any of the transitional phrases “comprising”, “consisting essentially of” and “consisting of.”
- The two most important denominators to the erection process and penis size are blood flow and vessel size. The compositions of the present invention are formulated with a combination of active ingredients that enhance blood flow to the area applied thereby resulting in erection or vasocongestion. The active ingredients in these compositions aid the body in the production of nitric oxide via the essential amino acid L-arginine. Additionally, these compositions function as powerful vasodilators using yohimbe, and methyl nicotinate to increase circulation, discourage clot formation, and reinforce the walls of the capillaries allowing for bigger, thicker blood vessels. These physiological actions are believed to be useful for the treatment of sexual dysfunction resulting from circulatory disorders. Additionally, these physiological actions are believed to strengthen blood vessel walls of the penis resulting in erectile enhancement. Further, herbal ingredients in these compositions can act to promote and enhance desire functioning as pro-libido agents.
- The compositions of the present invention contain one or more of the following active ingredients: methyl nicotinate, yohimbe extract, panax ginseng, L-arginine, muira puama, catuaba bark, maca, and saw palmetto.
- Methyl nicotinate is rubefacient and counterirritant for the relief of aches and pains in muscles, tendons, and joints. When applied to the skin, methyl nicotinate causes vasodilation of the surrounding blood vessels producing a feeling of warmth. This sensation competes with, and to some extent blocks, pain in underlying muscles and joints, since both feelings are conveyed by the same nerves. The compositions of the present invention may contain between about 0.1% and about 5% methyl nicotinate. Preferably, the compositions of the present invention contain between about 0.5% and about 2% methyl nicotinate. Most preferably, the compositions of the present invention contain about 1% methyl nicotinate. Suitable sources of methyl nicotinate for use in compositions of the present invention are available commercially. For example, methyl nicotinate is available commercially from Araer Chemicals.
- Yohimbe is a vasodilator used as a sensual stimulant for healthy men and women and to treat organic impotence. Yohimbe is thought to stimulate the pelvic nerve ganglia and is thus useful for the treatment of erection problems. Effects may include increased libido, increased sensation and increased stamina. The compositions of the present invention may include yohimbe extract prepared by extracting the yohimbe for one ounce of a plant material containing the herb into two ounces of a suitable liquid. Typically the extraction liquid is water or an alcohol. Prepared in this manner, compositions of the present invention may contain between about 5 drops and about 50 drops of the yohimbe extract in 120 cm3 of the topical composition of the present invention. Preferably, the compositions of the present invention contain between about 15 drops and about 35 drops of the yohimbe extract in four ounces of the topical composition. Most preferably, the compositions of the present invention contain about 25 drops of the yohimbe extract in four ounces of the topical composition. Herbal extracts containing yohimbe that are suitable for use in formulating compositions of the present invention are available commercially. For example, an herbal blend containing yohimbe that is suitable for use in compositions of the present invention is commercially available from Nature's Alternative.
- Panax ginseng is an herb thought to be an immune stimulant. Ginseng has a high content of the Rg1 group of ginsenosides which cause an increase in motor activity. It acts on the adrenal and pituitary glands and is thought to improve response to stress, increase mental and physical work capacity, increase concentration and mental activity, enhance mental acuity and intellectual and physical performance and benefit the immune system. The compositions of the present invention may include ginseng extract prepared by extracting ginseng from one ounce of a plant material containing the herb into two ounces of a suitable liquid. Typically the extraction liquid is water or an alcohol. Prepared in this manner, compositions of the present invention may contain between about 1 drop and about 30 drops of ginseng extract in four ounces of the topical composition. Preferably, the compositions of the present invention contain between about 5 drops and about 20 drops of ginseng extract in four ounces of the topical composition. Most preferably, the compositions of the present invention contain about 12 drops of ginseng extract in four ounces of the topical composition. Herbal extracts containing ginseng that are suitable for use in formulating compositions of the present invention are available commercially. For example, an herbal blend containing ginseng that is suitable for use in compositions of the present invention is commercially available from Nature's Alternative.
- L-arginine is an essential amino acid with vasodilatory properties. L-arginine is the primary nutrient that allows the body to create nitric oxide, which helps regulate every physiologic function in the body. L-arginine has been shown to reduce blood pressure, improve heart function, circulation, lower cholesterol, improve immune system response, wound healing, open airways in asthma and help with male sexual function. When arginine is introduced into the body, it interacts with the enzyme nitric oxide synthase which replaces a nitrogen molecule on arginine with an oxygen atom forming nitric oxide. The compositions of the present invention may contain between about 100 mg and about 400 mg of L-arginine per ounce of the topical composition. Preferably, the compositions of the present invention contain between about 200 mg and about 300 mg of L-arginine per ounce of the topical composition. Most preferably, the compositions of the present invention contain about 240 mg of L-arginine per ounce of the topical composition. L-arginine suitable for use in formulating compositions of the present invention is available commercially. For example, a commercial source of L-arginine that is suitable for use in compositions of the present invention is commercially available from T. J. Clark.
- Muira puama is a botanical isolated from a tree that grows in the rain forests of Brazil. Used as a mild tonic, this herb is thought to be useful in treating the symptoms of nervous problems and disorders such as neurasthenia, neuralgia and nervous depression. The compositions of the present invention may include muira puama extract prepared by extracting one ounce of muira puama plant material into two ounces of a suitable liquid. Typically the extraction liquid is an alcohol. Prepared in this manner, compositions of the present invention may contain between about 1 drop and about 30 drops of muira puama extract in four ounces of the topical composition. Preferably, the compositions of the present invention contain between about 5 drops and about 20 drops of muira puama extract in four ounces of the topical composition. Most preferably, the compositions of the present invention contain about 12 drops of muira puama extract in four ounces of the topical composition. Herbal extracts of muira puama that are suitable for use in formulating compositions of the present invention are available commercially. A concentrated extract that is suitable for use in compositions of the present invention is commercially available from Raintree Nutrition.
- Catuaba is a botanical extracted from the plant species Juniperis brasilinsis native to Brazil. It is reported to have benefits in relieving insomnia from hypertension, restless sleeping patterns and in helping to arrest failing memory. The compositions of the present invention may include catuaba extract prepared by extracting one ounce of catuaba bark into two ounces of a suitable liquid. Typically the extraction liquid is water or an alcohol. Prepared in this manner, compositions of the present invention may contain between about 1 drop and about 30 drops of catuaba extract in four ounces of the topical composition. Preferably, the compositions of the present invention contain between about 5 drops and about 20 drops of catuaba extract in four ounces of the topical composition. Most preferably, the compositions of the present invention contain about 12 drops of catuaba extract in four ounces of the topical composition. Herbal extracts containing catauba that are suitable for use in formulating compositions of the present invention are available commercially. For example, a catuaba bark extract suitable for use in compositions of the present invention is commercially available from Raintree Nutrition.
- Maca is a plant also known as Lepidium meyenii. Peruvian maca root is a vegetable root or tuber related to the potato and the Mexican wild yam. It contains amino acids, complex carbohydrates, vitamins B1, B2, B12, C and E and minerals, including calcium, phosphorus, zinc, magnesium and iron. This herb has traditionally been used to increase energy, vitality, stamina and endurance in athletes, promote mental clarity, as an aphrodisiac for both men and women, for male impotence, menstrual irregularities and female hormone imbalances, including menopause. The compositions of the present invention may include maca extract prepared by extracting one ounce of maca plant root material into two ounces of a suitable liquid. Typically the extraction liquid is water or an alcohol. Prepared in this manner, compositions of the present invention may contain between about 1 drop and about 30 drops of maca extract in four ounces of the topical composition. Preferably, the compositions of the present invention contain between about 5 drops and about 20 drops of maca extract in four ounces of the topical composition. Most preferably, the compositions of the present invention contain about 12 drops of maca extract in four ounces of the topical composition. Maca plant material suitable for use in preparing extracts for use in formulating compositions of the present invention are available commercially. For example, bulk maca plant material that is suitable for use in compositions of the present invention is commercially available from Raintree Nutrition.
- Saw Palmetto is an urinary antiseptic also known as Serenoa repens. This herb acts to tone and strengthen the male reproductive system and is used in cases of enlarged prostate gland. The compositions of the present invention may include saw palmetto extract prepared by extracting the saw palmetto from one ounce of a plant material containing the herb into two ounces of a suitable liquid. Typically the extraction liquid is water or an alcohol. Prepared in this manner, compositions of the present invention may contain between about 1 drop and about 30 drops of saw palmetto extract in four ounces of the topical composition. Preferably, the compositions of the present invention contain between about 5 drops and about 20 drops of saw palmetto extract in four ounces of the topical composition. Most preferably, the compositions of the present invention contain about 12 drops of saw palmetto extract in four ounces of the topical composition. Herbal extracts containing saw palmetto that are suitable for use in formulating compositions of the present invention are available commercially. For example, a saw palmetto extract that is suitable for use in compositions of the present invention is commercially available from Nature's Alternative.
- The compositions of the present invention can optionally include as active ingredients nettles and/or zinc. The components are widely available commercially.
- The compositions of the present invention may contain other ingredients that are not physiologically active but serve to enhance the pharmaceutical elegance of the final topical composition. For example, the compositions of the present invention may contain excipients such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidinone, cellulose, water, syrup, and methyl cellulose. Additionally, the compositions of the present invention may include lubricating agents such as talc, magnesium stearate and mineral oil, wetting agents, emulsifying and suspending agents, preserving agents such as methyl- and propylhydroxybenzoates, sweetening agents or flavoring agents.
- The compositions of the present invention may be formulated in any pharmaceutically acceptable topical vehicle that does not interact adversely with the active ingredients or, in the case of the embodiment which includes a coating of the compositions applied to one surface of a condom, does not interact adversely with the condom materials. For example, compositions of the present invention may be formulated in water or oil based topical vehicles. These compositions can include lanolin, aquaphor, methylcellulose and derivatives thereof, petroleum based vehicles, aloe and the like. Preferably, the compositions of the present invention are formulated in a topical, water-based vehicle containing aloe and vitamin E. Suitable topical vehicles containing aloe and vitamin E are available commercially. For example, a suitable topical vehicle for use in formulating compositions of the present invention containing aloe and vitamin E is available from T. C. Laboratories (Treasures Company).
- Preferably, the topical compositions of the present invention contain a mixture of distilled water, aloe barbadensis leafjuice, helianthus annus (sunflower) seed oil, stearic acid, glycine soja (soybean) oil, cetyl alcohol NF, emulsifying wax, olea Europaea (olive) fruit oil, glycerin, palmitic acid, cymbopogan schoenanthus (lemongrass) oil, mentha piperita (peppermint) oil, tocopherol, denatured alcohol, methyl salicylate, aloe barbadensis leaf extract, menthol, fragrance, camella sinensis (green tea) leaf extract, rosmarinus officinalis (rosemary) leaf extract, citrus grandis (grapefruit) seed extract, lecithin, sodium bicarbonate, ascorbyl palmitate, polysorbate 20, methylparaben, propylparaben, urtica dioica (nettles) extract or zinc oxide, having a pH of between about 5.0 and about 8.
- The compositions of the present invention are formulated for transdermal delivery of the active ingredients following topical administration to the penis or labia inajora and minora pudendi. A small amount of the compositions of the present invention is applied topically directly to the penis or labia majora and minora pudendi. Alternatively, in a preferred embodiment, the composition may be packaged as a coating on the interior surface of a condom. Thereby, upon use of the condom, the composition is applied topically to the penis.
- A preferred embodiment of the topical compositions of the present invention consists essentially of the following ingredients of a quality and purity suitable for topical application to a mammal:
Active ingredient Amount per 30 g ± 10% methyl nicotinate 0.3 g yohimbe extract 25 drops L-arginine 240 mg muira puama extract 12 drops catuaba bark extract 12 drops maca extract 12 drops saw palmetto 12 drops - These active ingredients were formulated in a base for topical administration in a pharmaceutically-acceptable topical vehicle containing distilled water, aloe barbadensis leaf juice, helianthus annus (sunflower) seed oil, stearic acid, glycine soja (soybean) oil, cetyl alcohol NF, emulsifying wax, olea Europaea (olive) fruit oil, glycerin, palmitic acid, cymbopogan schoenanthus (lemongrass) oil, mentha piperita (peppermint) oil, tocopherol, denatured alcohol, methyl salicylate, aloe barbadensis leaf extract, camella sinensis (green tea) leaf extract, rosmarinus officinalis (rosemary) leaf extract, citrus grandis (grapefruit) seed extract, lecithin, sodium bicarbonate, ascorbyl palmitate, polysorbate 20, methylparaben, propylparaben, mitica dioica (nettles) extract and zinc oxide, having a pH of about 6.0.
- A preferred embodiment of the topical compositions of the present invention consists essentially of the following ingredients of a quality and purity suitable for topical application to a mammal:
Active ingredient Amount per 30 g ± 10% methyl nicotinate 0.3 g L-arginine 240 mg muira puama extract 12 drops catuaba bark extract 12 drops maca extract 12 drops - These active ingredients were formulated in a base for topical administration in a pharmaceutically-acceptable topical vehicle containing distilled water, aloe barbadensis leaf juice, helianthus annus (sunflower) seed oil, stearic acid, glycine soja (soybean) oil, cetyl alcohol, emulsifying wax, olea europaea (olive) fruit oil, glycerin, palmitic acid, fragrance, tocopherol, denatured alcohol, methyl salicylate, aloe barbadensis leaf extract, camella sinensis (green tea) leaf extract, rosmarinus officinalis (rosemary) leaf extract, citrus grandis (grapefruit) seed extract, lecithin, sodium bicarbonate, ascorbyl palmitate, polysorbate 20, menthol, methylparaben, propylparaben, urtica dioica (nettles) extract and zinc oxide, having a pH of about 6.0.
- The foregoing description of the present invention has been presented for purposes of illustration and description. Furthermore, the description is not intended to limit the invention to the form disclosed herein. Consequently, variations and modifications commensurate with the above teachings, and the skill or knowledge of the relevant art, are within the scope of the present invention. The embodiment described hereinabove is further intended to explain the best mode known for practicing the invention and to enable others skilled in the art to utilize the invention in such, or other, embodiments and with various modifications required by the particular applications or uses of the present invention. It is intended that the appended claims be construed to include alternative embodiments to the extent permitted by the prior art.
Claims (10)
1. A composition formulated for topical administration to a mammal consisting of:
a vasodilating composition consisting of methyl nicotinate and methyl salicyclate, and
a water-based topical vehicle comprising water, aloe, green tea extract, a vegetable oil and at least one compound selected from the group consisting of stearic acid, sodium bicarbonate, cetyl alcohol, methyl paraben and propyl paraben.
2. The composition of claim 1 , wherein the composition contains about 0.1% methyl nicotinate.
3. The composition of claim 1 , wherein the vegetable oil is selected from the group consisting of soybean oil and sunflower oil.
4. The composition of claim 1 , wherein the water-based topical vehicle further comprises at least one of ascorbyl palmitate and tocopherol acetate.
5. A composition formulated for topical administration to a mammal consisting of:
a vasodilating composition consisting of L-arginine, methyl nicotinate and methyl salicyclate; and,
a water-based topical vehicle comprising water, aloe, green tea extract, a vegetable oil and at least one compound selected from the group consisting of stearic acid, sodium bicarbonate, cetyl alcohol, methyl paraben and propyl paraben.
6. The composition of claim 1 , wherein the composition contains about 0.1% methyl nicotinate.
7. The composition of claim 1 , wherein the vegetable oil is selected from the group consisting of soybean oil and sunflower oil.
8. The composition of claim 1 , wherein the water-based topical vehicle further comprises at least one of ascorbyl palmitate and tocopherol acetate.
9. A condom having an internal surface coating comprising a topical composition consisting of:
a vasodilating composition consisting of methyl nicotinate and methyl salicyclate, and
a water-based topical vehicle comprising water, aloe, green tea extract, a vegetable oil and at least one compound selected from the group consisting of stearic acid, sodium bicarbonate, cetyl alcohol, methyl paraben and propyl paraben.
10. A method of enhancing sexual response in a mammal comprising topically applying a composition consisting of:
a vasodilating composition consisting of methyl nicotinate and methyl salicyclate, and
a water-based topical vehicle comprising water, aloe, green tea extract, a vegetable oil and at least one compound selected from the group consisting of stearic acid, sodium bicarbonate, cetyl alcohol, methyl paraben and propyl paraben,
to the genitalia of a mammal in need of such treatment.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/745,421 US20070202199A1 (en) | 2003-02-07 | 2007-05-07 | Compositions for Enhancing Sexual Responsiveness |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44562403P | 2003-02-07 | 2003-02-07 | |
US10/775,574 US7214390B2 (en) | 2003-02-07 | 2004-02-09 | Topical compositions for enhancing sexual responsiveness |
US11/745,421 US20070202199A1 (en) | 2003-02-07 | 2007-05-07 | Compositions for Enhancing Sexual Responsiveness |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/775,574 Continuation US7214390B2 (en) | 2003-02-07 | 2004-02-09 | Topical compositions for enhancing sexual responsiveness |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070202199A1 true US20070202199A1 (en) | 2007-08-30 |
Family
ID=32869396
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/775,574 Expired - Fee Related US7214390B2 (en) | 2003-02-07 | 2004-02-09 | Topical compositions for enhancing sexual responsiveness |
US11/745,421 Abandoned US20070202199A1 (en) | 2003-02-07 | 2007-05-07 | Compositions for Enhancing Sexual Responsiveness |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/775,574 Expired - Fee Related US7214390B2 (en) | 2003-02-07 | 2004-02-09 | Topical compositions for enhancing sexual responsiveness |
Country Status (2)
Country | Link |
---|---|
US (2) | US7214390B2 (en) |
WO (1) | WO2004071437A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080020035A1 (en) * | 2002-08-28 | 2008-01-24 | Kedar Prasad | Micronutrient formulations and related methods of manufacture |
US7709428B2 (en) * | 2005-02-23 | 2010-05-04 | Ansell Healthcare Products Llc | Thickened spreadable warming lubricant |
US20060188528A1 (en) * | 2005-02-23 | 2006-08-24 | Ansell Healthcare Products Llc | Spreadable warming lubricant |
WO2008060817A2 (en) * | 2006-10-19 | 2008-05-22 | Blaise Harrison Llc | Exothermic personal lubricant |
WO2008106681A1 (en) * | 2007-03-01 | 2008-09-04 | Blaise Harrison, Llc | Exothermic condom packaging |
EP1992322A1 (en) * | 2007-05-11 | 2008-11-19 | Dr. Scheller Cosmetics AG | Composition for percutaneous application |
US20080311166A1 (en) * | 2007-06-14 | 2008-12-18 | Wimer Allan H | Cooling towel |
US20090197892A1 (en) * | 2007-08-21 | 2009-08-06 | Nawaz Ahmad | Anhydrous compositions useful for attaining enhanced sexual wellness |
US20090054497A1 (en) * | 2007-08-21 | 2009-02-26 | Nawaz Ahmad | Methods for attaining enhanced sexual wellness using anhydrous compositions |
US20090054498A1 (en) * | 2007-08-21 | 2009-02-26 | Nawaz Ahmad | Anhydrous Compositions Useful for Attaining Enhanced Sexual Wellness |
US8770201B2 (en) * | 2007-10-26 | 2014-07-08 | Glycobiosciences Inc. | Condom with multifunctional coating |
US20100263675A1 (en) * | 2009-04-21 | 2010-10-21 | Ansell Healthcare Products Llc | Condom with Localized Active Agent |
WO2009134767A1 (en) * | 2008-04-29 | 2009-11-05 | Ansell Healthcare Products Llc | Condom with localized active agent |
US20100124576A1 (en) * | 2008-11-14 | 2010-05-20 | Teri Amato | Topical Treatment Formulation of Natural Ingredients for Enhancing Sexual Response |
US8337882B2 (en) * | 2009-05-17 | 2012-12-25 | David Garrow | Personal stimulating wiping systems |
IT1401590B1 (en) * | 2010-08-03 | 2013-07-26 | Balzano | NEW SUBSTANCES FOR USE IN THE TREATMENT OF THE DROP OF LIBIDO FEMININO. |
US20120093950A1 (en) * | 2010-10-19 | 2012-04-19 | Klrm, Llc | Compositions and methods for treating, inhibiting the onset, and slowing the progression of erectile dysfunction including naturally occuring age related erectile dysfunction |
ITLI20110007A1 (en) * | 2011-09-10 | 2013-03-11 | Lloyds Internat Credit Llc | AN INNOVATIVE NATURAL COMPOSITION EFFECTIVE FOR THE CARE OF IMPOTENCE |
US10226418B2 (en) | 2014-05-12 | 2019-03-12 | Susie Q, Ltd. | Arginine-containing topical composition |
WO2016120844A1 (en) * | 2015-01-29 | 2016-08-04 | Giovanni Ferrari | Energizing mixture, particulary on sexual level |
IT201700007771A1 (en) * | 2017-01-25 | 2018-07-25 | Paolo Rizzi | CONDOMS AND PROCEDURE |
EP3609503A4 (en) * | 2017-04-12 | 2020-12-16 | Performance Labs Pte. Ltd. | Production of aspirin-triggered resolvins without the use of aspirin in a dietary omega-3 supplement |
IT201900006595A1 (en) * | 2019-05-07 | 2020-11-07 | Carlo Vicari | Formulation for the enhancement of sexual performance |
Citations (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145852A (en) * | 1989-07-11 | 1992-09-08 | Ronald Virag | Vaso-active medicament to treat impotence |
US5208031A (en) * | 1989-06-06 | 1993-05-04 | Kelly Patrick D | Sexual lubricants containing zinc as an anti-viral agent |
US5217997A (en) * | 1990-01-09 | 1993-06-08 | Levere Richard D | Use of l-arginine in the treatment of hypertension and other vascular disorders |
US5232935A (en) * | 1991-07-03 | 1993-08-03 | Dow Corning France S.A. | Composition for enhancing drug permeation |
US5240945A (en) * | 1992-02-18 | 1993-08-31 | Warshaw Thelma G | Method and compositions for treating acne |
US5318960A (en) * | 1992-06-03 | 1994-06-07 | Frank Toppo | System for transdermal delivery of pain relieving substances |
US5428070A (en) * | 1993-06-11 | 1995-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity |
US5451407A (en) * | 1993-06-21 | 1995-09-19 | Alza Corporation | Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug |
US5496827A (en) * | 1994-07-15 | 1996-03-05 | Patrick; Jay | Compositions for the transdermal delivery of nutrients |
US5543430A (en) * | 1994-10-05 | 1996-08-06 | Kaesemeyer; W. H. | Method and formulation of stimulating nitric oxide synthesis |
US5595753A (en) * | 1995-04-14 | 1997-01-21 | President And Fellows Of Harvard College | Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract |
US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US5895658A (en) * | 1997-09-17 | 1999-04-20 | Fossel; Eric T. | Topical delivery of L-arginine to cause tissue warming |
US5922332A (en) * | 1997-09-17 | 1999-07-13 | Fossel; Eric T. | Topical delivery of arginine to overcome pain |
US5985860A (en) * | 1992-06-03 | 1999-11-16 | Toppo; Frank | System for transdermal delivery of pain relieving substances |
US6007824A (en) * | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
US6036977A (en) * | 1995-09-29 | 2000-03-14 | L.A.M. Pharmaceutical Corp. | Drug preparations for treating sexual dysfunction |
US6117872A (en) * | 1998-06-23 | 2000-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity |
US6207713B1 (en) * | 1997-09-17 | 2001-03-27 | Eric T. Fossel | Topical and oral delivery of arginine to cause beneficial effects |
US6267995B1 (en) * | 1999-03-03 | 2001-07-31 | Pure World Botanicals, Inc. | Extract of Lepidium meyenii roots for pharmaceutical applications |
US6294517B1 (en) * | 1996-02-02 | 2001-09-25 | Nitromed, Inc. | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
US6323211B1 (en) * | 1996-02-02 | 2001-11-27 | Nitromed, Inc. | Compositions and methods for treating sexual dysfunctions |
US6368640B1 (en) * | 1998-04-03 | 2002-04-09 | The Daily Wellness Company | Method and composition for improving sexual fitness |
US6403658B1 (en) * | 2000-09-21 | 2002-06-11 | Shaina Toppo | Genital vasodilator |
US6428791B1 (en) * | 1999-04-13 | 2002-08-06 | Alphamed Pharmace Vticals, Corp | Lubrication composition |
US6476037B1 (en) * | 2000-03-23 | 2002-11-05 | The Regents Of The University Of California | L-arginine and phosphodiesterase (PDE) inhibitor synergism |
US20020165429A1 (en) * | 1999-07-01 | 2002-11-07 | 40 J's Llc | Clitoral sensitizing arrangements |
US20020173436A1 (en) * | 2000-09-20 | 2002-11-21 | Steffen Sonnenberg | Multiphase soaps |
US20020183297A1 (en) * | 2001-02-14 | 2002-12-05 | Niazi Sarfaraz K. | Pharmaceutical composition for the treatment of alopecia |
US20020187165A1 (en) * | 2001-05-15 | 2002-12-12 | Joseph F. Long | Composition for female sexual arousal |
US20030059484A1 (en) * | 1996-11-07 | 2003-03-27 | Lvmh Recherche | Cosmetic treatment method for fighting against skin ageing effects |
US6548841B2 (en) * | 2000-11-09 | 2003-04-15 | Texas Instruments Incorporated | Nanomechanical switches and circuits |
US6548087B1 (en) * | 1999-07-12 | 2003-04-15 | Frances B. Kent | Nutritional supplement |
US20030077296A1 (en) * | 2001-10-24 | 2003-04-24 | Denton Michael G. | Sense enhancing topical gel |
US6579543B1 (en) * | 2002-02-22 | 2003-06-17 | Jackie H. McClung | Composition for topical application to skin |
US20040102358A1 (en) * | 1997-05-19 | 2004-05-27 | Scivoletto Rosemarie | Composition for treating skin conditions |
US6803060B2 (en) * | 2000-09-07 | 2004-10-12 | Joe Reyes | Composition to boost libido |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3921591A1 (en) * | 1989-06-30 | 1991-01-03 | Weiss Gmbh & Co Leonhard | METHOD AND DEVICE FOR REMOVING VOLATILE POLLUTANTS FROM EARTH SOILS |
ZA995262B (en) * | 1998-08-19 | 2000-02-21 | Matthys Jacobus Booyens | Massage composition and method. |
-
2004
- 2004-02-09 US US10/775,574 patent/US7214390B2/en not_active Expired - Fee Related
- 2004-02-09 WO PCT/US2004/003819 patent/WO2004071437A2/en active Application Filing
-
2007
- 2007-05-07 US US11/745,421 patent/US20070202199A1/en not_active Abandoned
Patent Citations (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208031A (en) * | 1989-06-06 | 1993-05-04 | Kelly Patrick D | Sexual lubricants containing zinc as an anti-viral agent |
US5145852A (en) * | 1989-07-11 | 1992-09-08 | Ronald Virag | Vaso-active medicament to treat impotence |
US5217997A (en) * | 1990-01-09 | 1993-06-08 | Levere Richard D | Use of l-arginine in the treatment of hypertension and other vascular disorders |
US5232935A (en) * | 1991-07-03 | 1993-08-03 | Dow Corning France S.A. | Composition for enhancing drug permeation |
US5240945A (en) * | 1992-02-18 | 1993-08-31 | Warshaw Thelma G | Method and compositions for treating acne |
US5318960A (en) * | 1992-06-03 | 1994-06-07 | Frank Toppo | System for transdermal delivery of pain relieving substances |
US5985860A (en) * | 1992-06-03 | 1999-11-16 | Toppo; Frank | System for transdermal delivery of pain relieving substances |
US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US6646006B2 (en) * | 1993-06-11 | 2003-11-11 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US5428070A (en) * | 1993-06-11 | 1995-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity |
US5451407A (en) * | 1993-06-21 | 1995-09-19 | Alza Corporation | Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug |
US5496827A (en) * | 1994-07-15 | 1996-03-05 | Patrick; Jay | Compositions for the transdermal delivery of nutrients |
US5543430A (en) * | 1994-10-05 | 1996-08-06 | Kaesemeyer; W. H. | Method and formulation of stimulating nitric oxide synthesis |
US5767160A (en) * | 1994-10-05 | 1998-06-16 | Notol, Inc. | Method and formulation of stimulating nitric oxide synthesis |
US5595753A (en) * | 1995-04-14 | 1997-01-21 | President And Fellows Of Harvard College | Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract |
US6036977A (en) * | 1995-09-29 | 2000-03-14 | L.A.M. Pharmaceutical Corp. | Drug preparations for treating sexual dysfunction |
US6294517B1 (en) * | 1996-02-02 | 2001-09-25 | Nitromed, Inc. | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
US6323211B1 (en) * | 1996-02-02 | 2001-11-27 | Nitromed, Inc. | Compositions and methods for treating sexual dysfunctions |
US20030059484A1 (en) * | 1996-11-07 | 2003-03-27 | Lvmh Recherche | Cosmetic treatment method for fighting against skin ageing effects |
US20040102358A1 (en) * | 1997-05-19 | 2004-05-27 | Scivoletto Rosemarie | Composition for treating skin conditions |
US6207713B1 (en) * | 1997-09-17 | 2001-03-27 | Eric T. Fossel | Topical and oral delivery of arginine to cause beneficial effects |
US5922332A (en) * | 1997-09-17 | 1999-07-13 | Fossel; Eric T. | Topical delivery of arginine to overcome pain |
US5895658A (en) * | 1997-09-17 | 1999-04-20 | Fossel; Eric T. | Topical delivery of L-arginine to cause tissue warming |
US6368640B1 (en) * | 1998-04-03 | 2002-04-09 | The Daily Wellness Company | Method and composition for improving sexual fitness |
US6544563B2 (en) * | 1998-04-03 | 2003-04-08 | The Daily Wellness Company | Method and composition for improving sexual fitness |
US6117872A (en) * | 1998-06-23 | 2000-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity |
US6007824A (en) * | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
US6340480B1 (en) * | 1998-07-09 | 2002-01-22 | Melvin J. Duckett | Natural composition for the treatment of circulatory conditions |
US6267995B1 (en) * | 1999-03-03 | 2001-07-31 | Pure World Botanicals, Inc. | Extract of Lepidium meyenii roots for pharmaceutical applications |
US6428791B1 (en) * | 1999-04-13 | 2002-08-06 | Alphamed Pharmace Vticals, Corp | Lubrication composition |
US20020165429A1 (en) * | 1999-07-01 | 2002-11-07 | 40 J's Llc | Clitoral sensitizing arrangements |
US6548087B1 (en) * | 1999-07-12 | 2003-04-15 | Frances B. Kent | Nutritional supplement |
US6476037B1 (en) * | 2000-03-23 | 2002-11-05 | The Regents Of The University Of California | L-arginine and phosphodiesterase (PDE) inhibitor synergism |
US6803060B2 (en) * | 2000-09-07 | 2004-10-12 | Joe Reyes | Composition to boost libido |
US20020173436A1 (en) * | 2000-09-20 | 2002-11-21 | Steffen Sonnenberg | Multiphase soaps |
US6403658B1 (en) * | 2000-09-21 | 2002-06-11 | Shaina Toppo | Genital vasodilator |
US6548841B2 (en) * | 2000-11-09 | 2003-04-15 | Texas Instruments Incorporated | Nanomechanical switches and circuits |
US20020183297A1 (en) * | 2001-02-14 | 2002-12-05 | Niazi Sarfaraz K. | Pharmaceutical composition for the treatment of alopecia |
US20020187165A1 (en) * | 2001-05-15 | 2002-12-12 | Joseph F. Long | Composition for female sexual arousal |
US20030077296A1 (en) * | 2001-10-24 | 2003-04-24 | Denton Michael G. | Sense enhancing topical gel |
US6579543B1 (en) * | 2002-02-22 | 2003-06-17 | Jackie H. McClung | Composition for topical application to skin |
Also Published As
Publication number | Publication date |
---|---|
WO2004071437A3 (en) | 2005-04-28 |
US20040265400A1 (en) | 2004-12-30 |
WO2004071437A2 (en) | 2004-08-26 |
US7214390B2 (en) | 2007-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070202199A1 (en) | Compositions for Enhancing Sexual Responsiveness | |
US6200594B1 (en) | Breast-enhancing, herbal compositions and methods of using same | |
US8092844B2 (en) | Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions | |
EP2491938B1 (en) | Formulations for well-being | |
US6338862B1 (en) | Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors | |
WO2008031322A1 (en) | Application of acetylcholine esterase inhibitor medication of leonurus extractive as cholinomimetic | |
CN105233010A (en) | Wine capable of invigorating kidney and strengthening Yang and making method thereof | |
AU2008271573B2 (en) | Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions | |
EP1503775B1 (en) | Formulations useful in the treatment of male and female impotence | |
US11224603B2 (en) | Antihistamines in combination with a range of substances for improved health | |
EP3880222A1 (en) | Composition comprising ginseng, moringa and rutin and the use thereof in the treatment of male sexual dysfunctions | |
CN103494866A (en) | Formulation method of formula for treating waist-leg ache | |
WO2002051426A2 (en) | Compositions and methods for treating sexual dysfunction, enhancing sexual function, increasing testosterone levels, and improving muscle strength and mass | |
Mayo et al. | Premenstrual syndrome: a natural approach to management | |
CN102198184A (en) | Effect of morinda officinalis extract on improving or treating sexual disorder, and application thereof | |
KR20020071326A (en) | Composition for improving erectile dysfunction and foods containing the same | |
KR101879536B1 (en) | omposition comprising the extracts of Seasoning- Shinki-hwan for improving Penis Tumescence | |
KR20100006808A (en) | External using medicine for hair growth | |
KR20030071974A (en) | Pharmaceutical composition for medical treatment and prevention of obesity | |
RU2163806C1 (en) | Agent for treatment of men with sexual dysfunction | |
CN100525780C (en) | Compound breviscapine pills | |
US20060122261A1 (en) | [method of preparing labdane diterpene composition, preferably isoforskolin and deacetylforskolin from forskolin extract and their use for promoting lean body mass and other applications] | |
KR101399895B1 (en) | A pharmaceutical comprising the extract of Acorus gramineus Soland for treating or preventing erectile dysfunction | |
Holt | Part 2: stimulants and dietary supplements | |
UA151633U (en) | Method of obtaining a pharmaceutical composition for the treatment of cough |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BARMENSEN LABS, LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARONE, FRANK V.;JACOBSEN, CHRISTOPHER;CHUMENKO, KIRILL;REEL/FRAME:021488/0424 Effective date: 20040810 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |